CERO vs. MYNZ, SNSE, TXMD, FLGC, PMCB, CHRO, TLPH, KPRX, KLTO, and JAGX
Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), Flora Growth (FLGC), PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical products" industry.
CERo Therapeutics vs.
CERo Therapeutics (NASDAQ:CERO) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
CERo Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.
CERo Therapeutics has higher earnings, but lower revenue than Mainz Biomed.
29.6% of CERo Therapeutics shares are owned by institutional investors. 18.0% of CERo Therapeutics shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Mainz Biomed had 5 more articles in the media than CERo Therapeutics. MarketBeat recorded 5 mentions for Mainz Biomed and 0 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 0.00 beat Mainz Biomed's score of -0.20 indicating that CERo Therapeutics is being referred to more favorably in the media.
Mainz Biomed has a consensus price target of $67.00, suggesting a potential upside of 1,067.25%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts clearly believe Mainz Biomed is more favorable than CERo Therapeutics.
Mainz Biomed received 14 more outperform votes than CERo Therapeutics when rated by MarketBeat users.
Summary
Mainz Biomed beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks.
Get CERo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CERo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CERO) was last updated on 2/22/2025 by MarketBeat.com Staff
